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A B S T R A C T
Purpose
Tivantinib, a MET receptor tyrosine kinase inhibitor, demonstrated increased anticancer activity in
preclinical and early clinical studies when combined with erlotinib. Our study aimed to confirm
efficacy and safety of the combination in previously treated patients with non–small-cell lung
cancer (NSCLC).
Patients and Methods
Patients with advanced nonsquamous NSCLC previously treated with one to two systemic
regimens, including a platinum doublet, were randomly assigned at a 1:1 ratio to receive erlotinib
150 mg daily plus oral tivantinib 360 mg twice daily (E  T) or erlotinib plus placebo (E  P) until
disease progression. Tumor specimens were evaluated for EGFR and KRAS mutations, MET
expression, and MET gene amplification. The primary end point was overall survival (OS).
Secondary and exploratory objectives included progression-free survival (PFS), OS in molecular
subgroups, and safety.
Results
The study enrolled 1,048 patients and was discontinued for futility at the interim analysis. OS did
not improve with E T versus E P (median OS, 8.5 v 7.8 months, respectively; hazard ratio [HR],
0.98; 95% CI, 0.84 to 1.15; P  .81), even though PFS increased (median PFS, 3.6 v 1.9 months;
HR, 0.74; 95% CI, 0.62 to 0.89; P  .001). Exploratory subgroup analyses suggested OS
improvement in patients with high MET expression (HR, 0.70; 95% CI, 0.49 to 1.01). Most
common adverse events occurring with E  T versus E  P were rash (33.1% v 37.3%,
respectively), diarrhea (34.6% v 41.0%), asthenia or fatigue (43.5% v 38.1%), and neutropenia
(grade 3 to 4; 8.5% v 0.8%).
Conclusion
E  T was well tolerated and increased PFS but did not improve OS in the overall nonsquamous
NSCLC population.
J Clin Oncol 33:2667-2674. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Lung cancer is a leading cause of cancer-related
death, with approximately 1,825,000 new patient
cases and 1,590,000 deaths worldwide in 2012.1
Non–small-cell lung cancer (NSCLC) represents
85% of all lung cancers.2 For patients with locally
advanced or metastatic disease, systemic chemo-
therapy provides a modest but statistically signif-
icant improvement in survival.3 In the last 15
years, clinical research efforts with targeted agents
have endeavored to improve survival beyond cy-
totoxic chemotherapy.
Overexpression of the N-methyl-N=-
nitrosoguanidine human osteosarcoma transform-
ing gene (MET) or aberrant signaling of MET
receptor tyrosine kinase occurs in lung cancer and
other solid tumors. The involvement of MET in mul-
tiple signal transduction pathways affecting tumor-
cell proliferation, mobilization, and angiogenesis
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makes it an interesting potential target for cancer therapy.4-6 Tivan-
tinib (ARQ 197; ArQule, Woburn, MA; Daiichi-Sankyo, Tokyo, Ja-
pan) is an orally available selective small molecule that inhibits MET
receptor tyrosine kinase with a novel ATP-independent binding
mechanism, leading to inhibition of cell proliferation and induction of
apoptosis in MET-expressing cancer cells.7,8 Although epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors have shown
higher therapeutic activity when EGFR-sensitizing mutations are de-
tected,9 the EGFR inhibitor erlotinib (Tarceva; Genentech, San Fran-
cisco, CA) has demonstrated efficacy in previously treated patients
with advanced NSCLC.10,11 Consequently, dual inhibition of MET
and EGFR with the combination of tivantinib plus erlotinib was a
rational approach to be explored in advanced NSCLC. A randomized
phase II study of tivantinib plus erlotinib versus erlotinib alone in 167
patients with chemotherapy-pretreated, EGFR inhibitor–naive ad-
vanced NSCLC showed trends toward improved progression-free
(PFS) and overall survival (OS) in the nonsquamous NSCLC subpop-
ulation and improved PFS in the EGFR wild-type (WT) and KRAS-
mutant subpopulations.12 The objective of this phase III randomized,
double-blind, placebo-controlled study (MARQUEE [ARQ 197 Plus
Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-
Squamous, Non-Small-Cell Lung Cancer]) was to confirm the effi-
cacy and safety of tivantinib plus erlotinib versus erlotinib plus placebo
in previously treated patients with locally advanced or metastatic
nonsquamous NSCLC.13
PATIENTS AND METHODS
Patients
Eligible patients were adults age 18 years with histologically or cyto-
logically confirmed, locally advanced or metastatic (stage IIIb to IV) nonsqua-
mous NSCLC with measurable disease according to RECIST (version 1.1),14
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0
or 1, and adequate bone marrow, liver, and kidney functions. Patients had to
have received one or two prior systemic anticancer regimens, including prior
platinum-based chemotherapy, without prior exposure to EGFR inhibitors,
tivantinib, or any other MET inhibitor. Archival or fresh tissue samples for
biomarker analyses and EGFR mutation status were mandatory for all patients.
Patients with clinically unstable brain metastases or history of cardiac disease,
uncontrolled hypertension, or other active malignancies were excluded.
Study Design, Treatment, and Study Objectives
The study was conducted according to the Declaration of Helsinki and
approved by appropriate independent ethics committees or institutional re-
view boards at all sites. Patients provided written informed consent before
study participation and consent for tissue collection for biomarker assessment.
An independent data monitoring committee periodically reviewed safety data
and the interim analysis results.
After screening, patients were randomly assigned at a ratio of 1:1 to
receive oral erlotinib 150 mg once daily plus oral tivantinib 360 mg twice daily
(E T) or oral erlotinib 150 mg once daily plus matching placebo (E P).
Patients were stratified by number of prior therapies (one v two), sex (male v
female), smoking history (never v ever), and EGFR and KRAS mutation status
(mutant v WT or unknown). Treatment continued until unacceptable toxic-
ity, disease progression, or another discontinuation criterion was met. Tivan-
tinib or erlotinib dose delays of  14 days were permitted for grade  3
nonhematologic toxicities until resolution to grade 1 or baseline, and treat-
ment was reintroduced at a reduced dosage of one or both drugs depending on
the toxicity. For hematologic toxicities of grade 3 or platelet counts 50
109/L, tivantinib was withheld until absolute neutrophil and platelet counts
returned to baseline ( 1.5 109/L and 100 109/L, respectively).
The primary objective was OS in the intent-to-treat (ITT) population.
Secondary objectives included OS in the EGFR WT subgroup, PFS in the ITT
population, and safety. Exploratory analyses were performed for other pre-
defined subgroups and efficacy parameters. Tumor response was assessed by
investigators according to RECIST (version 1.1).14
Statistical Analysis
The study hypothesis was that E T would improve OS relative to E
P in the ITT population. For 90% power to detect a hazard ratio (HR) of 0.75
at a two-sided significance level of 0.01, 735 events were required. Assuming 18
months of enrollment, 12 additional months of follow-up, and a 9% rate of
loss to follow-up, the target enrollment was 988 patients.
An interim analysis was planned after approximately 50% of planned
events had occurred to allow early stopping for efficacy or futility. Stopping
boundaries were determined using the Lan-DeMets family with O’Brien-
Fleming parameters,15 while specifying nonbinding futility stopping
boundaries. At the first interim efficacy analysis with 485 events, the
one-sided P value stopping boundaries were .00055 for efficacy stopping
and .0743 for futility stopping.
OS and PFS were compared using stratified log-rank tests adjusting for
number of prior therapies, sex, and smoking history. Kaplan-Meier estimates
of the medians and corresponding 95% CIs were determined. An unstratified
Cox proportional hazards regression model was performed to obtain the point
estimate of the HR and 95% CI. Secondary efficacy end points were similarly
analyzed. Safety was assessed by the investigator based on the incidence and
severity of treatment-emergent adverse events (TEAEs) and their relationship
to either treatment arm.
Molecular Analyses
Biomarkers in archival or fresh tumor samples were analyzed in the
following order of priority: EGFR mutation, MET expression (determined by
immunohistochemistry), KRAS mutation, and MET gene amplification when
sufficient tumor tissue was available. Mutations in EGFR and KRAS were
determined by polymerase chain reaction analysis using the Qiagen Rotor-
Gene (Qiagen, Hilden, Germany) at central laboratories (Covance, Indianap-
olis, IN; Geneva, Switzerland); existing mutation results were used if they were
from accredited local laboratories. MET expression was analyzed at a central
laboratory (LabCorp, Research Triangle Park, NC) using the SP44 rabbit
monoclonal antibody (Ventana Medical Systems, Tucson, AZ). MET expres-
sion was defined as high if membranous staining intensity was2 in50% of
tumor cells. On the basis of limited MET epitope stability, MET analyses by
immunohistochemistry must have been performed within 90 days of section-
ing to be considered valid. MET gene copy number and chromosome 7 copy
number were determined by fluorescence in situ hybridization using probes
(LSI D7S486) for MET (7q31) and CEP7 (Abbott Molecular, Des Plaines, IL).
RESULTS
Patient Population and Disposition
Between January 2011 and July 2012 in Europe and Russia, the
United States, Latin America, Canada, and Australia, 1,624 patients
were screened, 576 failed to meet inclusion or exclusion criteria, and
1,048 were randomly assigned (ET, n526; EP, n522; Fig 1).
Of these patients, 976 (93%) subsequently discontinued study treat-
ment, and two were lost to follow-up. The most common reason for
treatment discontinuation was progressive disease (E T, n 295;
EP, n 350). Patients received study treatments for a mean of 16.2
weeks (range, 0.1 to 84.0) in the E T group and 13.9 weeks (range,
0.1 to 92.0) in the E P group.
The preplanned interim OS analysis was performed after 485
deaths, and the result crossed the protocol-defined stopping boundary
for futility. Consequently, the independent data monitoring commit-
tee recommended study discontinuation, even though there were no
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safety concerns, and PFS had improved. Blinding of treatment assign-
ment was maintained, and patients receiving treatment were allowed
to continue. A data cutoff was applied on December 15, 2012, at which
time 614 survival events (58.6%) had occurred (E  T, n  300
[57.0%]; E  P, n  314 [60.2%]). Results for the EGFR-mutant
subpopulation were immature, and the study was continued for these
patients and those receiving study treatment with clinical benefit.
Patient Characteristics
Among the 1,048 randomly assigned patients, treatment groups
were well balanced for baseline demographics and clinical character-
istics (Table 1). Median age was 62.0 years (range, 24 to 89 years);
59.1% of patients were men, 81.0% were either current or former
smokers, 93.0% had adenocarcinoma, and approximately two thirds
had received only one prior systemic therapy.
Nearly all patients had EGFR mutation status determined, with
89.4% having EGFR WT tumors (Table 2). Among 986 patients with
known tumor KRAS mutation status, 28.8% were KRAS mutant. Of
1,048 randomly assigned patients, 445 tumor samples were investi-
gated for MET expression by immunohistochemistry, and 47.4% of
these had high expression. A total of 476 patients had samples evalu-
able for MET amplification assessment: 54 (11.3%) had MET copy
number 4, and four patients (two in each arm) had MET amplifi-
cation with MET:CEP7 ratio  2. No patient had a MET:CEP7
ratio 5.
Efficacy
OS did not differ significantly between treatment groups in the
ITT population (HR, 0.98; 95% CI, 0.84 to 1.14; P  .81; Fig 2A).
Median OS was 8.5 versus 7.8 months for the E T and E P arms,
respectively. Similarly, OS was not significantly different (median OS:
ET, 7.2 months; EP, 7.1 months; HR, 1.00; 95% CI, 0.85 to 1.18;
P .94) within the EGFR WT subgroup, which comprised approxi-
mately 89.4% of the ITT population. In contrast to OS, tivantinib
significantly increased median PFS in the ITT population (HR, 0.74;
95% CI, 0.64 to 0.85; P .001) from 1.9 to 3.6 months (Fig 2B). In the
EGFR WT subgroup, PFS was also significantly longer (HR, 0.72; 95%
CI, 0.62 to 0.83; P .001) with E T than with E P (median PFS,
2.7 v 1.9 months).
Subgroup Analyses
In the preplanned exploratory analysis of the subgroup of 211
patients with high MET tumor expression, a trend for OS benefit
favoring ET was observed (median OS, 9.3 v 5.9 months; HR, 0.70;
95% CI, 0.49 to 1.01; Fig 3A). PFS also improved in the subgroup of
patients with high MET expression (median, 3.7 v 1.9 months; HR,
0.72; 95% CI, 0.52 to 0.99; Fig 3B). No association was observed
between tivantinib treatment and other biomarker and demographic
subgroups (Fig 4). Longer OS was observed in tumors with MET gene
copy number  4 (HR, 0.83; 95% CI, 0.43 to 1.61), but the limited
sample size precluded any meaningful conclusion. For the EGFR-
mutant subgroup (n 109), OS and PFS data at the cutoff time are
still immature, with only 30 deaths.
EGFR and KRAS mutations were almost completely exclusive of
each other, whereas MET expression was independent of EGFR and
KRAS genotypes. Among fully defined molecular subgroups, the larg-
est was EGFR WT, KRAS WT, and MET low (n 143), where OS did
not improve (median OS: ET, 7.5 months; EP, 6.4 months; HR,
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Fig 1. CONSORT diagram.
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1.09; 95% CI, 0.72 to 1.65). In the EGFR WT, KRAS WT, and MET
high subgroup (n 119), OS was prolonged for E T (median OS:
ET, 8.8 months; EP, 5.0 months; HR, 0.56; 95% CI, 0.35 to 0.89).
Response to Treatment
The overall objective response rate (ORR) was 10.3% (95% CI,
8.0 to 13.2) with ET and 6.5% (95% CI, 4.7 to 9.0) with EP. The
disease control rate (objective response plus stable disease) was 45.8%
in patients receiving ET (95% CI, 41.6 to 50.1) and 32.0% in those
receiving E P (95% CI, 28.1 to 36.1). Median duration of objective
response was 40.4 weeks with E T and 47.9 weeks with E P.
Postdiscontinuation Therapy
After study treatments were discontinued, 192 (36.5%) of 526
patients in the ET group and 231 (44.3%) of 522 in the EP group
received subsequent therapy, primarily chemotherapy (ET, 29.5%;
E P, 38.8%).
Exploratory Multivariable Cox Regression
A stepwise forward and backward model selection approach was
taken in an exploratory multivariable Cox regression analysis with treat-
ment retained in the model. Potential prognostic factors, including EGFR
genotype, KRAS genotype, MET expression, age, baseline ECOG PS, sex,
number of prior lines of therapy for NSCLC, smoking history, best re-
sponsetopriortherapy,andregion,werefitintotheCoxregressionmodel
along with the interaction with treatment. In the stepwise multivariable
analysis, the final model for OS selected the following factors: EGFR
genotype,best responsetoprior therapy,ECOGPS(andinteraction), line
of prior therapy, MET expression (and interaction), region, and smoking
history. Notable interactions with treatment were observed, prompting
closer examination of the subgroups (Fig 4).
Safety
In the safety population of 1,037 patients who received any dose
of study drug, 1,016 (98.0%) experienced at least one TEAE: 513
(98.7%) in the ET group and 503 (97.3%) in the E P group. The
most common TEAEs in the ET versus EP group were fatigue or
asthenia (43.5% v 38.1%, respectively), diarrhea (34.6% v 41.0%),
rash (33.1% v 37.3%), and decreased appetite (29.0% v 28.8%; Table
3). Myelosuppression, a known toxicity of tivantinib, was observed in
this study. TEAEs related to myelosuppression for ET versus EP
included anemia (16.0% v 9.9%), neutropenia (11.9% v 1.9%), leuko-
penia (5.8% v 1.0%), and febrile neutropenia (3.3% v 0.4%). Grade
3 TEAEs were 8.5% v 0.8% for neutropenia and 6.3% v 2.9% for
anemia, respectively. Eight patients developed interstitial lung disease
(ILD; E T, n 3; E P, n 5). Bradycardia was reported in 14
Table 1. Patient Baseline Demographic and Clinical Characteristics
(ITT population)
Characteristic
Erlotinib Plus
Tivantinib (n  526)
Erlotinib Plus
Placebo (n  522)
No. (%) No. (%)
Age, years
Mean 61.2 61.1
SD 10.1 9.8
Median 62.0 61.0
Range 26-89 24-87
Sex
Female 216 (41.1) 213 (40.8)
Male 310 (58.9) 309 (59.2)
Race
White 430 (81.7) 446 (85.4)
Black 16 (3.0) 12 (2.3)
Asian 8 (1.5) 5 (1.0)
Other or not reported 71 (13.5) 59 (11.3)
Smoker
Never 101 (19.2) 98 (18.8)
Ever 425 (80.8) 424 (81.2)
Current 98 (18.6) 97 (18.6)
Former 327 (62.2) 327 (62.6)
ECOG PS
0 168 (31.9) 168 (32.2)
1 357 (67.9) 353 (67.6)
2 1 (0.2) 1 (0.2)
Tumor stage at study entry
IIIb 22 (4.2) 14 (2.7)
IV 499 (94.9) 501 (96.0)
Not reported 5 (1.0) 7 (1.3)
NSCLC histologic type
Adenocarcinoma 480 (91.3) 495 (94.8)
Large-cell carcinoma 31 (5.9) 20 (3.8)
Other nonadenocarcinoma 15 (2.8) 7 (1.4)
Unclassified nonadenocarcinoma 7 (1.3) 3 (0.6)
Prior NSCLC radiotherapy
Yes 232 (44.1) 219 (42.0)
No 294 (55.9) 303 (58.0)
Prior NSCLC surgery
Yes 238 (45.2) 253 (48.5)
No 288 (54.8) 269 (51.5)
No. of prior NSCLC systemic
therapies
1 346 (65.8) 348 (66.7)
2 180 (34.2) 174 (33.3)
Brain metastases 66 (12.5) 80 (15.3)
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group perfor-
mance status; ITT, intent to treat; NSCLC, non–small-cell lung cancer; SD,
standard deviation.
Table 2. Tumor Biomarkers Status (ITT population)
Characteristic
Erlotinib Plus
Tivantinib (n  526)
Erlotinib Plus
Placebo (n  522)
No. (%) No. (%)
EGFR mutation status
Mutant 56 (10.6) 53 (10.2)
Wild type 469 (89.2) 468 (89.7)
Unknown 1 (0.2) 1 (0.2)
KRAS mutation status
Mutant 136 (25.9) 148 (28.4)
Wild type 356 (67.7) 346 (66.3)
Unknown 34 (6.5) 28 (5.4)
MET expression status
High 104 (19.8) 107 (20.5)
Low 107 (20.3) 127 (24.3)
Unknown 315 (59.9) 288 (55.2)
MET FISH status
Positive 27 (5.1) 27 (5.2)
Negative 195 (37.1) 227 (43.5)
Unknown 304 (57.8) 268 (51.3)
Abbreviations: FISH, fluorescent in situ hybridization; ITT, intent to treat;
MET, mesenchymal-epithelial transition.
MET gene copy number  4.
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patients (2.7%) receiving ET and none of the patients receiving E
P; two cases in the E T group were grade 3.
During the study, 614 patients (59.2%) died, mainly as a result of
disease progression (E T, 46.0%; E P, 48.4%). Of all deaths, 142
(13.7% of safety population) were classified as TEAEs (ET, 14.8%;
E P, 12.6%), most related to underlying disease, leaving 66 deaths
related to a TEAE other than disease progression (ET, 6.2%; EP,
6.6%). The most common reasons for death in these patients receiving
E  T versus E  P were respiratory failure (1.0% v 1.2%, respec-
tively), sepsis or septic shock (1.0% v 0.2%), and pneumonia or bron-
chopneumonia (0.6% v 1.0%). Five deaths (1.0%) with E  T and
three deaths (0.6%) with E  P were considered associated with
tivantinib or placebo. At least one serious adverse event (SAE) oc-
curred in 410 patients (E  T, 42.1%; E  P, 36.9%), the most
common being respiratory events, as expected. Differences in SAE inci-
dence between E  T and E  P treatment groups, respectively, were
generally related to myelosuppression: anemia (3.1% v 1.2%), febrile
neutropenia (2.9% v 0.4%), and neutropenia (2.1% v 0.2%). There was
also a higher incidence of the following SAEs with E T versus E P,
respectively: pneumonia (3.8% v 2.1%) and sepsis (1.0% v 0.4%).
DISCUSSION
This phase III study did not meet its primary end point of improved
OS in previously treated patients with locally advanced or metastatic
No. at risk (cumulative events)
Erlotinib + 526 397 296 150 62 18 2 0 0
  tivantinib (0) (116) (207) (259) (288) (299) (300) (300) (300)
Erlotinib + 522 405 294 154 69 20 8 3 0
  placebo (0) (111) (212) (268) (299) (311) (313) (314) (314)
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Fig 2. (A) Overall survival (OS) and (B) progression-free survival (PFS) for patients receiving erlotinib plus tivantinib versus erlotinib plus placebo (intent-to-treat
population). HR, hazard ratio.
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Erlotinib + tivantinib 104 76 3.7 (2.0 to 3.9)
Erlotinib + placebo 107 77 1.9 (1.8 to 2.2) 
HR (unstratified), 0.72 (95% CI, 0.52 to 0.99)
Stratified log-rank test: P = .01
Fig 3. (A) Overall (OS) and (B) progression-free survival (PFS) for MET-high subgroup. HR, hazard ratio.
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nonsquamous NSCLC, although significant improvement in PFS and
increased ORR were observed. In addition, an exploratory analysis
indicated OS and PFS benefit with tivantinib in the subgroup of
patients with MET-high status by immunohistochemistry. In the sub-
group of patients with tumor MET gene copy number 4, there was
no difference in OS between treatment groups, but only four patients
had selective MET amplification with a MET:CEP7 ratio  2. Al-
though the drugs were well tolerated, the survival benefit may have
been diminished by the associated adverse events (AEs), such as asthe-
nia or fatigue and neutropenia.
In another recent phase III trial of tivantinib plus erlotinib com-
pared with tivantinib plus placebo in previously treated Asian patients
with nonsquamous NSCLC and EGFR WT, OS and PFS were also
numerically prolonged in patients receiving tivantinib. However, the
study was discontinued early because of toxicity concerns related to
the incidence of ILD—a known AE observed in Japanese patients
treated with EGFR inhibitors—in the tivantinib plus erlotinib
group.16 In our study, which did not include Asian patients, the com-
bination of tivantinib plus erlotinib was generally well tolerated. AE
profiles were similar between treatment groups, with the exception of
more frequent neutropenia and anemia with tivantinib. The combi-
nation of tivantinib with erlotinib did not increase the known risk of
ILD associated with erlotinib.17
Aberrant activation of the hepatocyte growth factor/MET signal-
ing pathway through MET gene amplification and/or high MET pro-
tein expression is known to occur in many solid tumors.6,18 Phase I
and II studies of tivantinib as monotherapy or in combination with
other agents in patients with different tumor types, including NSCLC,
have indicated a potential benefit for tivantinib and possible roles of
MET protein expression, MET amplification, and KRAS mutation as
predictive markers of efficacy.12,19-24 Although our phase III study did
not meet its primary end point, the data suggest a potential benefit in
patients with high MET expression, consistent with the hypothesis
that MET expression could be a potential biomarker for activity in this
setting. Recent in vitro studies have reported that tivantinib has activ-
ity against cells that harbor little or undetectable levels of MET,
suggesting additional mechanisms of action, including tubulin
inhibition25-27 or the possible involvement of cellular mechanisms28
and signaling pathways activated by MET.29 Although it is unclear the
Favors tivantinib Favors placebo
2.01.00.5
Factor n Hazard Ratio 95% CI
 
All 1,048 0.98 0.84 to 1.15
 
EGFR
  Mutant 109 0.72 0.35 to 1.48
  Wild type 937 1.00 0.85 to 1.18
 
KRAS
  Mutant 284 1.04 0.78 to 1.40
  Wild type 702 0.94 0.77 to 1.14
  Unknown 62 1.46 0.69 to 3.07
 
MET
  High 211 0.70 0.49 to 1.01
  Low 234 0.90 0.64 to 1.26
  Unknown 603 1.13 0.92 to 1.39
 
ECOG PS
  0 336 0.78 0.57 to 1.07
  1 710 1.10 0.91 to 1.32
 
Age, years
  < 65 646 0.84 0.69 to 1.03
  ≥ 65 402 1.27 0.98 to 1.64
 
Sex
  Female 429 0.87 0.68 to 1.13
  Male 619 1.06 0.86 to 1.29
 
Previous regimen
  1 694 0.95 0.78 to 1.16
  2 354 1.03 0.79 to 1.34
Fig 4. Forest plot of overall survival
hazard ratio by predefined subgroups.
ECOG PS, Eastern Cooperative Group per-
formance status; MET, mesenchymal-
epithelial transition expression.
Table 3. Treatment-Emergent AEs in  15% of Patients in Either
Treatment Group
AE
Erlotinib Plus Tivantinib
(n  520)
No. (%)
Erlotinib Plus Placebo
(n  517)
No. (%)
All Grades Grade  3 All Grades Grade  3
Fatigue or asthenia 226 (43.5) 47 (9.0) 197 (38.1) 41 (7.9)
Diarrhea 180 (34.6) 13 (2.5) 212 (41.0) 19 (3.7)
Rash 172 (33.1) 10 (1.9) 193 (37.3) 20 (3.9)
Decreased appetite 151 (29.0) 15 (2.9) 149 (28.8) 15 (2.9)
Dyspnea 136 (26.2) 46 (8.8) 117 (22.6) 38 (7.4)
Nausea 121 (23.3) 4 (0.8) 123 (23.8) 9 (1.7)
Cough 110 (21.2) 6 (1.2) 91 (17.6) 4 (0.8)
Dermatitis acneiform 90 (17.3) 7 (1.3) 98 (19.0) 11 (2.1)
Vomiting 73 (14.0) 5 (1.0) 81 (15.7) 6 (1.2)
Anemia 83 (16.0) 33 (6.3) 51 (9.9) 15 (2.9)
Abbreviation: AE, adverse event.
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effect that such activity may have in the clinical setting, data from this
and other randomized phase II trials demonstrate that tivantinib has
greater survival benefit in patients with high MET expression.19,23
Several other agents have shown efficacy in patients with specific
molecular aberrations in NSCLC. Crizotinib, an oral tyrosine kinase
inhibitor of MET, is indicated for the treatment of anaplastic
lymphoma kinase–positive metastatic NSCLC.30-32 It has also demon-
strated antitumor activity in a small group of patients with MET-
amplified advanced NSCLC, defined as selective gene amplification
with MET:CEP7 ratio 1.8 to 2.2 (low), 2.2 to 5 (intermedi-
ate), and  5 (high).33,34 In comparison, only four patients in our
study had selective MET gene amplification with a MET:CEP7 ratio
2.0, and only one had a ratio 3.0.
Onartuzumab—a monovalent monoclonal antibody targeting
the MET receptor—in combination with erlotinib in a phase II study
of patients with advanced NSCLC with high MET expression by im-
munohistochemistry improved OS and PFS.35 However, a subsequent
randomized phase III trial performed in patients with advanced
NSCLC with high MET expression was stopped early for futility.36 The
determination of high MET expression in both onartuzumab studies
seemed to be generally similar (immunohistochemistry staining in-
tensity 2 in 50% of tumor cells using SP44 antibody), but some
methodologic details are unavailable.35,36 As additional investigations
of targeted agents are conducted in patients with MET-high NSCLC,
an appropriate definition of MET-high status will be critical to identify
those patients who will benefit most from MET-targeted therapies.
In summary, the addition of tivantinib to erlotinib was well
tolerated but did not improve survival in the overall population of
patients with nonsquamous NSCLC, although PFS and ORR were
improved. Further investigation of tivantinib in patients with nons-
quamous NSCLC with high MET expression is warranted, as is explo-
ration of the most relevant tumor biomarkers to select patients for
combined MET and EGFR inhibition therapy.
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